Moderately early postnatal corticosteroids (PCs) (7–14 d after birth) v control for preterm infants with or at risk of chronic lung disease*
| Weighted event rates | |||||
|---|---|---|---|---|---|
| Outcomes | Number of studies (n) | Early PCs | Control | RRR (95% CI) | NNT (CI) |
| Chronic lung disease (CLD) at 28 days | 6 (623) | 76% | 87% | 13% (6 to 19) | 10 (6 to 17) |
| CLD at 36 weeks postmenstrual age | 5 (247) | 34% | 55% | 38% (18 to 53) | 5 (3 to 12) |
| Death or CLD at 28 days | 4 (520) | 82% | 96% | 14% (9 to 19) | 8 (6 to 13) |
| Death or CLD at 36 weeks postmenstrual age | 5 (247) | 45% | 72% | 37% (22 to 49) | 4 (3 to 7) |
| Need for late steroids | 5 (545) | 12% | 24% | 50% (29 to 65) | 9 (6 to 17) |
| RRI (95% CI) | NNH (CI) | ||||
|---|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, RRI, NNT, NNH and CI calculated from data in article using a fixed effects model. | |||||
| Hyperglycaemia | 7 (659) | 35% | 23% | 51% (20 to 90) | 9 (6 to 20) |
| Hypertension | 6 (599) | 8% | 3% | 173% (25 to 495) | 20 (13 to 100) |
| Hypertrophic cardiomyopathy | 3 (168) | 27% | 8% | 229% (50 to 620) | 6 (4 to 12) |
| Gastrointestinal bleeding | 3 (485) | 14% | 8% | 74% (2 to 198) | 17 (undefined to 10) |
| Infection | 7 (659) | 33% | 24% | 35% (6 to 71) | 12 (7 to 50) |